Duramed Pharmaceuticals Partners with Cardinal Health and Cardinal MarketFORCE for Distribution and Sales of Cenestin
* Cardinal Health Subsidiary Focuses on Product Launch Services * Cardinal MarketFORCE Senior Management Brings In-Depth Experience Marketing to Specialists and Primary Care Physicians in Women's Health
CINCINNATI, March 30 /PRNewswire/ -- Duramed Pharmaceuticals, Inc. (Nasdaq: DRMD - news) today announced that it has finalized an agreement to partner with Cardinal MarketFORCE, a Cardinal Health, Inc. (NYSE: CAH - news) offering that provides contract sales and marketing services, for launch-related and ongoing sales, marketing and distribution support for Cenestin(TM) (synthetic conjugated estrogens, A). Cenestin, the new plant-derived synthetic conjugated estrogens product for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, was approved for marketing by the U.S. Food and Drug Administration on March 24, 1999.
Under the terms of the three-year agreement, Cardinal will recruit, train and deploy a team of dedicated, full-time sales professionals and experienced sales managers. The team will have the critical mass necessary to reach the targeted women's health market. In addition, Cardinal's Distribution Company will work with Duramed to maximize initial Cenestin stocking and product awareness. In return, Duramed will compensate Cardinal according to a fixed schedule with performance incentives for achievement of certain market share targets. At the end of the three-year period, the sales team will transition to full-time Duramed employees.
|
